DelveInsight’s “Malignant Mesothelioma – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Malignant Mesothelioma, historical and forecasted epidemiology as well as the Malignant Mesothelioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Report:
- The annual incidence of Mesothelioma in the United States is estimated to be approximately 3,300 cases per year.
- Around 70% of MM develops from documented asbestos exposure, usually after a 30–40 years latency period.
- Malignant Mesothelioma (MM) is a rare tumor with an incidence
- In Europe, the average incidence of MM is 20 per million inhabitants/year.
Key benefits of the Report
1. Malignant Mesothelioma market report covers a descriptive overview and comprehensive insight of the Malignant Mesothelioma epidemiology and Malignant Mesothelioma market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Malignant Mesothelioma market report provides insights on the current and emerging therapies.
3. Malignant Mesothelioma market report offers a global historical and forecasted market covering drug outreach in 7 MM.
4. Malignant Mesothelioma market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Malignant Mesothelioma market.
Request for Sample Pages : https://www.delveinsight.com/sample-request/malignant-mesothelioma-market
“As per DelveInsight’s analysts, men are more often affected than women, and the incidence in males in the US is 1.5 per 100,000 per year.”
Malignant Mesothelioma (MM) is a relatively rare but aggressive form of cancer most frequently a result of inhaling asbestos arising from the membrane covering the lungs and the inner side of the ribs. The symptoms of MM include breathlessness, cough, chest pain, fatigue, fevers, persistent cough, loss of appetite and unexplained weight loss, swollen figures and constipation. There is an extremely poor prognosis and a vast majority of MM patients who are diagnosed in an advanced stage.
The major subtypes of MM, which are defined as per the histology (appearance under the microscope) includes Epithelial MM (the most common form and makes up about 60% of all cases), Sarcomatoid MM (comprises about 10% of all cases and these tumors display a somewhat more aggressive behavior) and mixed/biphasic (20%). The remainder of cases are comprised of the Mixed, or Biphasic variant of MM that contains elements of both Epithelial and Sarcomatoid MM.
Malignant Mesothelioma (MM) is a rare, but severe form of cancer, with an incidence that varies significantly within and among different countries around the world. It develops in about one to two persons per million of the general population, leading to thousands of deaths every year worldwide. Asbestos represents the predominant etiological factor, with approximately 70% of cases of MM with well‐documented occupational exposure to asbestos, with the exposure time, on average greater than 40 years.
“As per DelveInsight insights, the incidence varies between 7 per million in Japan.”
Some of the key companies working on Malignant Mesothelioma are:
- SELLAS Life Sciences Group
- Aduro Biotech
And Many Others.
The launch of the emerging therapies is expected to significantly impact the Malignant Mesothelioma treatment scenario in the upcoming years:-
And Many Others.
Request a Free Sample Report @ https://www.delveinsight.com/sample-request/malignant-mesothelioma-market
Table Of Contents:
1. Key Insights
2. Malignant Mesothelioma: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Malignant Mesothelioma in 2017
2.2. Total Market Share (%) Distribution of Malignant Mesothelioma in 2030
3. Malignant Mesothelioma: Disease Background and Overview
4. Epidemiology and Patient Population
4.1. Key Findings
5. Total Cases of Malignant Mesothelioma in 7MM
6. United States Epidemiology
7. EU5 Epidemiology
7.1. Germany Epidemiology
7.2. France Epidemiology
7.3. Italy Epidemiology
7.4. Spain Epidemiology
7.5. United Kingdom Epidemiology
8. Japan Epidemiology
9. Treatment and Management of Malignant Mesothelioma
9.1. Malignant Mesothelioma: Practical Diagnostic and Treatment Guidelines, 4th Edition- the USA
9.2. UK guidelines for diagnosis, referral, and management in primary and secondary care for
Malignant Mesothelioma in adults
10. Unmet Needs
11. Emerging Therapies
12. Malignant Mesothelioma: 7MM Market Analysis
12.1. Key Findings
12.2. Market Size of Malignant Mesothelioma in 7MM
13. United States: Market Outlook
14. EU-5 countries: Market Outlook
14.2. France Market Size
14.3. Italy Market Size
14.4. Spain Market Size
15. United Kingdom Market Size
16. Japan Market Outlook
17. Market Drivers
18. Market Barriers
19.1. Report Methodology
20. DelveInsight Capabilities
22. About DelveInsight
The Malignant Mesothelioma report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Malignant Mesothelioma across the complete product development cycle, including all clinical and nonclinical stages.
The Malignant Mesothelioma epidemiology covered in the report provides historical as well as forecasted Malignant Mesothelioma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NEVADA 89107
Country: United States